Evogene Ltd.
Evogene Ltd. is a computational chemistry company that uses generative AI to design small molecules for pharmaceutical and agricultural applications. The company is based in Israel and operates through its public listings in the United States and Israel, with technology developed around its ChemPass AI platform.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueComputational tools used to generate and optimize novel small molecules.
Crop-protection molecule programs and related ag-biological development work.
Small-molecule programs and partner-enabled discovery work for pharma uses.
Partnership-based R&D services, milestones, and technology access arrangements.
Customers
Evogene serves pharmaceutical and agricultural industry partners that need early-stage molecule discovery, optimization, and validation. Its buyers typically include companies seeking external innovation, access to AI-driven discovery tools, or differentiated crop-protection candidates. The business model depends on converting internal platform capability into partner programs and product opportunities.
Buy crop-protection discovery programs and molecular design capabilities to source differentiated fungicides, herbicides, or other actives.
Buy AI-enabled small-molecule discovery and optimization services for therapeutic programs.
Partner on platform access, shared research, and milestone-based development programs.
Strategy
Evogene’s strategy is to commercialize its generative AI chemistry platform through internal product development and strategic partnerships. The company focuses on turning computational molecule design into differentiated candidates with a higher probability of development success, especially in agricultural and pharmaceutical applications. Maintaining market access and listed status also remains important because it supports financing, visibility, and partner credibility.
Partnerships help convert the platform into near-term program value and external validation.
Agrochemical candidates are the clearest route to product-level value creation.
Multiple end markets can diversify revenue opportunities and improve platform economics.
Geography
Evogene is headquartered in Israel and lists on both Nasdaq and the Tel Aviv Stock Exchange. Its business is global in orientation because agricultural and pharmaceutical discovery programs are typically partnered internationally, while the company’s research and corporate functions are centered in Israel. The report excerpts also indicate exposure to Israel-specific geopolitical risk and reliance on external third parties for trials and studies.
Risks
Evogene’s business depends on successful third-party execution, technical validation, and partner adoption of its discovery platform. The company also faces capital-market and listing risk, since Nasdaq compliance and access to financing can affect its ability to fund development programs. As an Israel-based company, it is additionally exposed to regional geopolitical instability and to the inherent uncertainty of R&D-heavy agricultural and pharmaceutical discovery.
- Nasdaq listing complianceImpact: HighLikelihood: High
The company disclosed efforts to regain compliance with the minimum bid price requirement.
Exposure: Nasdaq Capital Market listing
- R&D and commercialization failureImpact: HighLikelihood: High
Discovery-stage molecules may not prove effective, safe, or partnerable.
Exposure: Ag and pharma pipelines
- Third-party execution failureImpact: HighLikelihood: Medium
Field trials and pre-clinical studies are performed by third parties, creating schedule and quality risk.
Exposure: R&D programs
- Geopolitical disruption in IsraelImpact: HighLikelihood: Medium
The company cited the war involving Israel and Iran/Hezbollah as a risk factor.
Exposure: Israel operations
Accounting
Judgemental itemsThe company recorded financing expenses and income tied to warrant revaluation, affecting net results.
Impact: Non-cash volatility in financing line items
Lavie Bio and related assets were sold, so the company reports separate discontinued-op results.
Impact: Improves comparability of continuing operations
Partner and collaboration receipts may be recognized over time or upon milestones.
Impact: Revenue timing and balance-sheet contract liabilities
Grant balances are carried as liabilities and can affect reported expenses and funding visibility.
Impact: Other liabilities and income statement presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Evaxion A/S
EVAX · Biological Products, (No Diagnostic Substances)
Evaxion A/S is a clinical-stage biotech company focused on developing vaccines and other drug candidates using its AI-Immunology™ platform.
Compugen Ltd
CGEN · Biological Products, (No Diagnostic Substances)
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Nuvation Bio Inc.
NUVB · Pharmaceutical Preparations
Purple Biotech Ltd
PPBT · Pharmaceutical Preparations
Evotec SE
EVO · Pharmaceutical Preparations
Evotec SE is a life science company that provides drug discovery and development services across small molecules, biologics, cell therapies, and related modalities.
Last updated: 28/09/2026